Posted: May 25, 2017
Minnesota has joined the now 33 states that have enacted legislation to provide access and proper regulation to the use of biosimilar medications, as HF712 received approval from the Governor. HF712 provides that within 5 business days of dispensing a biological product to a patient, the pharmacist must communicate the specific product and manufacturer to the prescribing physician.
Minnesota joins Nevada in making final action on biosimilar legislation this week, while Maryland's bill awaits action from its Governor.
For more information on all types of patient advocacy, continue to track the CSRO website and also visit our Facebook page.